12/07/2025
🌿 The Future of Diabetes & Weight Management: GLP‑1 Receptor Agonists
A 2025 review by Dr. Samuel Seidu (published in Drugs) explores how GLP‑1 receptor agonists (GLP‑1RAs)—like semaglutide, liraglutide, dulaglutide, and tirzepatide—are transforming care for people with type 2 diabetes and obesity.
đź’‰ How They Work:
These medications mimic the natural hormone GLP‑1, helping your body release insulin when needed, reduce appetite, slow digestion, and lower blood sugar—all while supporting sustainable weight loss.
❤️ Beyond Blood Sugar:
GLP‑1RAs don’t just manage diabetes—they protect the heart and kidneys, reducing cardiovascular events and slowing kidney disease progression.
⚖️ Safety & Side Effects:
Most people experience only mild, short‑term effects like nausea or bloating. Serious risks such as pancreatitis or thyroid issues remain rare and unconfirmed in large studies.
🚀 What’s Next:
Newer versions, including oral semaglutide and dual agonists like tirzepatide, offer even greater benefits with easier dosing and stronger weight‑loss results.
✨ Why It Matters:
GLP‑1RAs are reshaping how we think about metabolic health—treating not just diabetes, but the whole person.
